Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017

  • ID: 4311859
  • Report
  • 35 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ArmaGen Inc
  • GlaxoSmithKline Plc
  • RegenxBio Inc
  • Shire Plc
  • MORE
Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017, provides an overview of the Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline landscape.

Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. Symptoms include vision problems leading to blindness, personality changes, and motor disturbances such as clumsiness, muscle weakness (hypotonia), rigidity, inability to coordinate movement (ataxia), and/or muscle spasms especially of the neck, spine, arms, and legs. Treatment for metachromatic leukodystrophy is symptomatic and supportive.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Metachromatic Leukodystrophy (MLD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Metachromatic Leukodystrophy (MLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Metachromatic Leukodystrophy (MLD) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Metachromatic Leukodystrophy (MLD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Metachromatic Leukodystrophy (MLD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Metachromatic Leukodystrophy (MLD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Metachromatic Leukodystrophy (MLD) (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Metachromatic Leukodystrophy (MLD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ArmaGen Inc
  • GlaxoSmithKline Plc
  • RegenxBio Inc
  • Shire Plc
  • MORE
  1. Introduction
  2. Metachromatic Leukodystrophy (MLD) - Overview
  3. Metachromatic Leukodystrophy (MLD) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Metachromatic Leukodystrophy (MLD) - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Metachromatic Leukodystrophy (MLD) - Companies Involved in Therapeutics Development
  15. ArmaGen Inc
  16. GlaxoSmithKline Plc
  17. Recursion Pharmaceuticals LLC
  18. RegenxBio Inc
  19. Shire Plc
  20. Metachromatic Leukodystrophy (MLD) - Drug Profiles
  21. AGT-183 - Drug Profile
  22. Product Description
  23. Mechanism Of Action
  24. R&D Progress
  25. DUOC-01 - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. GSK-2696274 - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. MGTA-456 - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. SHP-611 - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. Small Molecules for Metachromatic leukodystrophy - Drug Profile
  46. Product Description
  47. Mechanism Of Action
  48. R&D Progress
  49. Stem Cell Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile
  50. Product Description
  51. Mechanism Of Action
  52. R&D Progress
  53. Metachromatic Leukodystrophy (MLD) - Dormant Projects
  54. Metachromatic Leukodystrophy (MLD) - Discontinued Products
  55. Appendix
  56. Methodology
  57. Coverage
  58. Secondary Research
  59. Primary Research
  60. Expert Panel Validation
  61. Contact Us
  62. Disclaimer
List of Tables:
  1. Number of Products under Development for Metachromatic Leukodystrophy (MLD), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Universities/Institutes, H1
  6. Number of Products by Stage and Target, H1
  7. Number of Products by Stage and Mechanism of Action, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Metachromatic Leukodystrophy (MLD) - Pipeline by ArmaGen Inc, H1
  11. Metachromatic Leukodystrophy (MLD) - Pipeline by GlaxoSmithKline Plc, H1
  12. Metachromatic Leukodystrophy (MLD) - Pipeline by Recursion Pharmaceuticals LLC, H1
  13. Metachromatic Leukodystrophy (MLD) - Pipeline by RegenxBio Inc, H1
  14. Metachromatic Leukodystrophy (MLD) - Pipeline by Shire Plc, H1
  15. Metachromatic Leukodystrophy (MLD) - Dormant Projects, H1
  16. Metachromatic Leukodystrophy (MLD) - Discontinued Products, H1
List of Figures:
  1. Number of Products under Development for Metachromatic Leukodystrophy (MLD), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Stage and Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Routes of Administration, H1
  8. Number of Products by Stage and Routes of Administration, H1
  9. Number of Products by Molecule Types, H1
  10. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ArmaGen Inc
  • GlaxoSmithKline Plc
  • Recursion Pharmaceuticals LLC
  • RegenxBio Inc
  • Shire Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll